
The innovative design of the DRUP-like trials: enabling access and providing evidence

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani

National Funder's Committee for Evaluation of Specialised
Medicines and Companion Diagnostics; CZ Health Insurance,
Leiden University Medical Centre, the Netherlands




Disclosure

Grant: European Commission Horizon Europe Mission on Cancer (no. 101104269): Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials, PRIME-ROSE.

Member of the National Horizon Scanning group for oncology and haematology

Advisor of Dutch Cancer Society KWF

More than half of the listed indications for oncology drug in the Netherlands are off-label



Mostly
chemotherapy

Will MAH be able to get the new indication on-label?

Yes

Off-label use will not
be evaluated *

* An exemption may apply to
treatments that are extremely
effective and cost-effective

No

Next slide

MAH will probably not register the indication


Due to loss market exclusivity and patent protection

Evaluation of off-label indication

Other (unknown) reasons....


Extremely rare genomic aberrations

Unequal access and no structured assessment of benefits



Drug Rediscovery platform for rare tumours/ rare mutations


Metastatic cancer with actionable aberrations



Van der Velden et al, Nature 2019


Van Waalwijk van Doorn-Khosrovani et al., Ann Oncol 2019

Personalised reimbursement for DRUP



Generating evidence in the third stage of DRUP

Drug Rediscovery Protocol (DRUP) is embedded in our reimbursement system



Van der Velden et al, Nature 2019

Van Waalwijk van Doorn-Khosrovani et al., Ann Oncol 2019

Geurts, de Wit, Zeverijn et al. JCO. 2023 41:16_suppl, 2590

DLCTs- DRUP-Like Clinical Trials



Thank you!